BioPharma Dive May 29, 2024
Michael Gibney

A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.

Complex problems sometimes call for practical solutions. As some cancer patients face waitlists for cell therapy, the industry is looking for new ways to make treatments available sooner and at lower cost. One partnership between a cell engineering platform startup and a modular robotics maker could help ease the bottleneck.

Drug delivery specialist Portal Biotechnologies and robotics maker Multiply Labs have teamed up with the goal of creating a “cartridge” for genetic engineering that combines cell-busting technology with automated robotic laboratories.

Portal Biotechnologies, led by former SQZ Biotech CEO Armon Sharei, has a platform for the “mechanical disruption...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Robotics/RPA, Technology, Trends
Related Articles:
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article